Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Hepatocellular 222Liver Neoplasms 68Neoplasms 18Pancreatic Neoplasms 16Neoplasm Metastasis 14Colorectal Neoplasms 12Rectal Neoplasms 8Stomach Neoplasms 7Colonic Neoplasms 7Carcinoma, Renal Cell 6Carcinoma 6Liver Diseases 5Gallbladder Neoplasms 5Breast Neoplasms 5Digestive System Neoplasms 4Bile Duct Neoplasms 4Prostatic Neoplasms 3Kidney Neoplasms 3Esophageal Neoplasms 3Adenocarcinoma 3Neoplasms, Glandular and Epithelial 2Neoplasms by Site 2Neoplasms by Histologic Type 2Multiple Myeloma 2Melanoma 2Hepatoblastoma 2Hepatitis C 2Hepatitis B 2Hematologic Neoplasms 2Glioblastoma 2

Interventions

Ribavirin 3sofosbuvir-velpatasvir drug combination 2elbasvir-grazoprevir drug combination 2Sorafenib 2telaprevir 1rocakinogene sifuplasmid 1pembrolizumab 1peginterferon alfa-2a 1navitoclax 1menatetrenone 1hepatitis C immune globulin, human 1grazoprevir 1elbasvir 1Sofosbuvir 1Rapid Diagnostic Tests 1Raltegravir Potassium 1Patient Navigation 1Mass Screening 1Introns 1Immunoglobulin G 1Immunoenzyme Techniques 1Hypothermia, Induced 1Enzyme-Linked Immunosorbent Assay 1Chromatography, High Pressure Liquid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hepatitis C × Sorafenib × Gastrointestinal × Clear all
NCT04710641 2025-03-06

OUTREACH2

Mina Alpha Limited

Phase 2 Completed
8 enrolled
Gastrointestinal

Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular

NCT02143401 2024-11-22

Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
29 enrolled
Gastrointestinal

Fibrosis, Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡